GY036 for stage 3/4 gynecologic cancers with pathogenic BRCA 1/2 mutation or HR deficiency - Clinical Trial

Adultos

NRG-GY036, un ensayo de fase III de uno vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy (NCT#06580314)